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Individual risk of type 2 diabetes (T2D) is modified by perturbations of adipose
mass, distribution and function. To investigate mechanisms responsible, we
explored the molecular, cellular, and whole-body effects of T2D-associated
alleles near KLF14. We show that KLF14 diabetes-risk alleles act in adipose
tissue to reduce KLF14 expression, and modulate, in trans, expression of
>400 genes. We demonstrate that, in human cellular studies,
reduced KLF14 expression increases pre-adipocyte proliferation but disrupts
lipogenesis, and, in mice, adipose-specific deletion of Klf14 partially
recapitulates the human phenotype of insulin resistance, dyslipidemia and
T2D. We show that KLF14 T2D risk-allele carriers shift body fat from gynoid to
abdominal stores, and display a marked increase in adipocyte cell size: these
effects on fat distribution, and the T2D-association, are female-specific.
Metabolic risk associated with variation at this imprinted locus depends on
both the sex of the subject, and of the parent from whom the risk-allele
derives.
The replicated genome-wide significant T2D association signal at chr7q32.3
maps to a 45kb recombination interval, extending from 3kb to 48kb upstream
of KLF141,2 (Figure 1a-c). In previous work based on microarray-derived RNA
expression data, KLF14, which encodes an imprinted transcription factor, was
exposed as the likely cis-effector gene for this locus in subcutaneous adipose
tissue1 and revealed to be a trans-regulator of a programme of adipose tissue
expression3. The KLF family of zinc-finger binding proteins have wide-ranging
regulatory roles in biological processes such as proliferation, differentiation
and growth4,5. However, little is known about KLF14, a single exon gene
whose transcription is limited to the maternally inherited chromosome in
embryonic, extra-embryonic, and adult tissue in humans and mice6.
RESULTS
Adipose-specific regulation of KLF14 mediates the T2D association
Using RNAseq data from subcutaneous adipose biopsies collected from 776
female twin members of the TwinsUK cohort7, we confirmed the cis-
expression quantitative trait locus (eQTL) (using rs4731702 T2D risk allele C
as the reference, β=-0.56, P=1.8x10-36) and identified a 38-fold-expanded
trans-network of 385 genes (false discovery rate (FDR) <5%)
(Supplementary Table 1, Figure 2). The KLF14 cis and trans effects were
robust, replicating in three independent studies of subcutaneous adipose
expression (MGH8, METSIM9 and deCODE10) (Figure 2c; Supplementary
Table 1, Supplementary Table 2). Despite detectable KLF14 expression in a
range of tissues, these cis- and trans-associations were completely adipose-
specific with no eQTL signal evident in (a) skin, whole blood and
lymphoblastoid cell lines (LCL) from the same TwinsUK individuals7 (Figure 1f,
Figure 2d); (b) T2D-relevant tissues such as muscle11, liver8,12, and islet13; or
(c) the broader coverage represented in eQTL datasets such as GTEx14
(Supplementary Table 3). KLF14 is imprinted, and as with the T2D-
association1, the KLF14 cis and trans eQTLs were maternal-specific – the
paternally inherited allele had no effect on KLF14 expression
(Supplementary Figure 1, Supplementary Table 4). All other genes within
300kb of the interval are also imprinted, but paternally-expressed, confirming
KLF14 as the likely mediator of the T2D association at this locus.
We first sought to refine the location of the causal variant(s) responsible for
these associations. The T2D association could not be resolved beyond a set
of 29 SNPs in high mutual linkage disequilibrium (LD, r2>0.94 in UK10K); the
apparent European-specificity of the T2D association15 precludes trans-ethnic
fine-mapping. The ancestral T2D-risk allele varies in global frequency (EUR =
54%, ASN=69%, AMR=58%, AFR=73%) but we could detect no evidence of
positive selection (Supplementary Figure 2, Supplemental Note). We
utilized chromatin state maps to annotate the associated interval, identifying a
~1.6kb enhancer ~5kb upstream of KLF14. This enhancer encompasses five
of the 29 associated variants and shows marked tissue-specificity: in
ChromHMM predictions from ENCODE16 and Roadmap17, it is annotated as
active in 10 (out of 127) cell types and tissues, three of them derived from
adipose tissue, including adipocytes and adipose-derived mesenchymal stem
cells (Figure 1d). The enhancer is also active in certain blood cells, but there
was no corresponding cis-eQTL18-20, making it unlikely that transcriptional
regulation in blood cells contributes to the GWAS phenotypes. There were no
other adipose active enhancers in the region.
As methylation is one of the key processes related to enhancer function, we
explored population-level methylation data at this locus in many of the same
TwinsUK individuals. The T2D-risk haplotype was associated with increased
methylation levels at Illumina 450K array probe cg02385110, ~3kb upstream
of KLF14, in subcutaneous adipose tissue (n=603, P=2.2x10-7, β=0.01 for
rs4731702) but not whole blood (n=309, P=0.69) or skin (n=437, P=0.39)
(Figure 1e-i). There was a consistent direction of effect across these
analyses in adipose: the T2D risk-haplotype was associated with increased
methylation and decreased RNA expression, and cg02385110 methylation
and KLF14 expression were negatively correlated. A second probe
(cg08097417), located at the KLF14 transcription start site has been
associated with age in whole blood21 and adipose tissue samples22. However,
this probe lies outside the T2D-association interval, and cg08097417
methylation was not related to KLF14 expression (P=0.36) or risk-haplotype
(P=0.99), indicating that age-related variability of cg08097417 is unrelated to
KLF14 expression or disease pathogenesis (Supplementary Figure 3).
Instead, we conclude that T2D-associated risk attributable to this locus is
likely to be consequence of sequence variation at the adipose enhancer
upstream of KLF14 and is marked by altered methylation.
The KLF14 variants regulate a large adipose-specific trans network
The trans-network regulated by the KLF14 variants is remarkable both for its
size and robust replication. Consistent with the known function of KLF14 as
both transcriptional activator and repressor, the trans-associations included
both positive and negative effects (Figure 2a, Supplementary Table 1).
Mediation analysis applied to the RNA expression data supported a causal
role for KLF14 expression in regulation of many of the trans-genes (161/385
genes passed Bonferroni-corrected Sobel’s mediation P<1.3x10-4).
The principal trans-regulatory mechanism appears to be direct interaction of
KLF14 with trans-gene cis-regulatory elements; the 20kb regions upstream of
the 385 trans genes were enriched both for KLF14 binding peaks in empirical
CHiPSeq data23 from HEK293T cells (P=2x10-4) and the presence of the
proposed KLF14 binding motif (Normalized Enrichment Score=4.17,
P=1.5x10-5). We assessed functional annotation of the trans-genes using
ToppGene24, and found the subset of 177 trans-genes with KLF14 binding-
motifs to be enriched for “metabolic pathways” (q=1.2×10-3) and “binding by
PPARG and RXRA during adipocyte differentiation” (q=3.9x10-8)
(Supplementary Table 5). Further subsetting, defining 122 trans-genes
enriched for both KLF14 binding motifs and KLF14 ChIP-seq peaks revealed
broadly similar functional enrichment (“binding by PPARG and RXRA during
adipocyte differentiation”: q=0.04; “metabolic pathways”: q=2.6x10-4).
A sub-network of 18 trans-genes showed enrichment for SREBF1 binding
motifs (NES=4.22, P=1.2x10-5), 11 of which did not have KLF14 motifs
(Figure 2b). The sub-network of SREBF1 motif-containing trans-genes was
enriched for “cholesterol biosynthesis and lipid metabolism” (q=2.8×10-7)
(Supplementary Table 5). SREBF1, a transcription factor involved in
cholesterol homeostasis, is itself a trans-gene directly regulated by KLF14
and appears to act as an intermediary in the regulation of this sub-network.
The human trans-network includes several genes with functions that make
them attractive candidates for mediating the range of KLF14-associated
phenotypes. These include SLC2A4 and IDE, which encode the GLUT4
transporter and insulin degrading enzyme, respectively. GLUT4 mediates
glucose uptake in adipose tissue and skeletal muscle, among other tissues,
and adipose-specific reduction in SLC2A4 expression levels has been
reported in T2D25. IDE degrades peptides including insulin, glucagon, and
amylin, and maps to a long-established T2D genome-wide association study
(GWAS) interval15. Notably, at multiple trans-genes, we identified adipose cis-
eQTLs coincident with metabolic-trait GWAS SNPs (r2>0.8) including three
known T2D loci (STARD10, C6orf57 and CDK2AP1) (Supplementary Table
6). This shows that local regulation of these genes can mediate T2D-
susceptibility independent of trans-regulation via KLF14, and indicates that
the phenotypic consequences of KLF14 variation are likely mediated by
multiple genes within the trans network.
Sex-specific metabolic trait associations implicate insulin action
Previous studies have demonstrated that T2D-risk alleles at KLF14 are, in
non-diabetic individuals, associated with increased fasting insulin26 and
reduced high density lipoprotein (HDL)-cholesterol27,28, emphasizing a primary
impact on insulin action rather than insulin secretion. By collecting data from
the largest-available GWA meta-analyses for multiple traits26,28-31, we have
extended the spectrum of KLF14 association to encompass a broad range of
insulin resistant, “metabolic syndrome” phenotypes including low density
lipoprotein (LDL)-cholesterol, triglycerides, waist-hip ratio and the HOMA-IR
measure of insulin sensitivity32 (Table 1). Crucially, as demonstrated in
Shungin et al31, the impact of KLF14 variation was far more marked on fat
distribution rather than overall adiposity (as measured by body mass index
(BMI)), with a particularly strong association between the T2D-risk allele and
reduced hip circumference (β=-0.017, P=1.6x10-6).
Sex-stratified reanalysis of these GWAS data revealed that, for all traits with
available data, effect sizes in females substantially exceeded those in males
(Table 1). The associations with hip circumference, triglycerides, LDL and
fasting insulin were exclusive to females, while the HDL, WHR and T2D
associations displayed a strong female-bias (e.g. T2D: female P=2.2x10-6,
odds ratio (OR) 1.14 [1.08-1.20]; male P=0.002, OR 1.08 [1.03-1.14]). In
UKBiobank (N=118,192), we found significant SNPxSex interactions for Hip
Circumference (P=3.1x10-7) and Waist Hip Ratio adjusted for BMI (P=3.9 x 10-
6), but not for Waist Circumference (P=0.06) or BMI (P=0.43). In a
combination of UKBiobank, Wellcome Trust Case Control consortium and The
Resource for Genetic Epidemiology on Adult Health and Aging (GERA)
samples (13,728 cases; 129,911 controls), rs4731702 and sex interacted to
influence T2D-risk (P=6.6x10-3).
These analyses demonstrate that the metabolic and anthropometric
consequences of KLF14 variation are dependent on both the parental origin of
the risk-allele and the sex of the recipient of that allele. Based on combining
these sex-specific ORs with the known imprinting-related maternal-specificity
of these associations1, we estimate that the point estimate for the per-allele
OR for T2D is ~1.28 in women inheriting the risk-allele from their mother. In
contrast, although KLF14 expression in adipose tissue was higher in females
than males across all genotype classes, we found no equivalent sex-
difference in the magnitude of the adipose cis-eQTL effect (Figure 3a,
Supplementary Table 4). To further explore drivers of the sexual dimorphism
in KLF14 expression levels, we compared KLF14 expression level between
86 pre-menopausal and 487 post-menopausal females from TwinsUK.
Individuals taking hormone replacement therapy were excluded from this
analysis. There was no association between KLF14 expression and
menopausal status (P=0.81) and the cis-eQTL effect size in each group was
comparable, suggesting gonadal steroids do not underlie the observed sexual
dimorphism in KLF14 expression levels. We conclude that the sex-
dependency of the whole body phenotype is not the direct consequence of
sexual dimorphism at the cis-regulatory level.
The genetic associations were consistent with our observations using gene
expression levels in the TwinsUK cohort. KLF14 gene expression in adipose
tissue was associated with a combined insulin resistance phenotype
characterized by increased fasting insulin and triglycerides, and reduced HDL
cholesterol (P=1.08x10-3). KLF14 trans-genes also showed enrichment for
association between trans-gene expression levels and the same combined
insulin resistance phenotype (P=1.82x106) (Supplementary Table 7- 8). We
used Dual energy X-ray Absorptiometry (DXA)-derived body composition data
from the same TwinsUK individuals to further dissect the impact on fat
distribution. Whilst there was no association between KLF14 expression in
subcutaneous adipose tissue and total fat volume (P=0.56) or BMI (P=0.27),
there were differences with respect to the distribution of that fat, including an
inverse association with abdominal visceral fat (P=0.02) and with the ratio of
android:gynoid fat (P=1.7x10-3). In many other insulin-resistant settings,
abnormalities of fat distribution are associated with ectopic deposition of fat
including the liver, leading to non-alcoholic fatty liver disease. However, we
found no evidence that KLF14 risk variants influence liver fat deposition,
whether measured directly (P=0.26, N=7,176)33 or indirectly via disturbed liver
function (alanine aminotransferase (ALT) P=0.79, gamma-glutamyl
transferase (GGT) P=0.89, N=61,089)34.
These data indicate that genetically-determined reduction in cis-expression of
KLF14 in adipose results in an insulin-resistant and T2D-predisposing
phenotype, which, in women only, is characterized by, and potentially
mediated by, a shift in fat distribution from relatively inert gynoid stores to
more metabolically-active abdominal deposition.
Conserved mouse phenotypes
We generated mice carrying an adipose-specific Klf14 deletion allele through
the combination of a CRISPR-Cas9-generated conditional allele with Klf14-
flanking loxP sites and adipose-specific (Adipoq) Cre recombinase and
compared these mice with wildtype Cre-expressing colony mates. Adipose-
specific knockout mice of both sexes (null on both maternal and paternal
chromosomes) displayed a broad pattern of insulin resistance phenotypes:
HDL-C was reduced (16 weeks, significant only in females), triglycerides
increased (16 weeks, significant only in males) (Figure 4a,b), and both
glucose tolerance and insulin sensitivity were impaired in both sexes at 12
weeks (Figure 4c-f).
We also characterised two mouse-lines in which Klf14 expression was
reduced globally. The first mouse (Klf14tm1(KOMP)Vlcg; generated within KOMP)
featured deletion of the entire single exon of Klf14. The second mouse,
designed to minimise any disruption of adjacent regulatory sequences, used
CRISPR-Cas9 genome editing to induce a 7bp frameshift indel allele. There
were some inconsistencies between the models, but the predominant
phenotype was a reduction in HDL-C (Supplementary Figures 4a and 5a)
with a modest and/or transitory effect on glucose homeostasis
(Supplementary Figures 4b,c,d and 5d,e). The HDL-C phenotype seen in
global deletion mice mirrors the phenotype reported following hepatic-specific
deletion of Klf1435.
RNASeq analysis of subcutaneous fat taken from both the adipose Klf14 KO
and the Klf14tm1(KOMP)Vlcg global deletion mouse recovered some, but not all,
features of the trans-network seen in humans. In the adipose-specific Klf14
KO mouse (N=8), 18 genes were differentially expressed at FDR q<0.05 (or
1286 with p<0.05). The latter set (of 1286 nominally significant mouse trans-
genes) was significantly enriched for overlap with the human trans-network
(P<2x10-4). In the Klf14tm1(KOMP)Vlcg global deletion mouse (N=16), we confirmed
this overlap (P<1x10-6 with the human trans network) in the 285 genes
differentially expressed compared to controls (FDR q<0.05): 5’ noncoding
sequences for these genes were also enriched for the presence of the Klf14
binding motif (P<0.001). Although Srebf2 (the mouse ortholog of SREBF1) is
directly regulated by Klf14, we did not detect enrichment of the murine trans-
genes for the Srebf2 motif. The murine trans-genes were enriched for relevant
functional categories, including “response to lipid” (q=4.4x10-5), “triglyceride
metabolic process” (q=2.3x10-3), “response to steroid hormone” (q=2.7x10-3)
and “regulation of cell proliferation” (q=3.2x10-3) (Supplementary Table 9).
Thus, adipose-specific deletion of Klf14 in mice recapitulates many aspects of
the phenotype associated with variants that influence adipose-specific cis-
regulation of KLF14 in humans, but the absence of sex specificity, and
differences in the molecular consequences of Klf14 perturbation place limits
on the relevance of murine models for this gene.
KLF14 impacts glucose uptake, lipogenesis and cell size
Members of the KLF family are involved in transcriptional control of adipocyte
development and function5, but the role of KLF14 in adipogenesis is unknown.
To evaluate the role of KLF14 in adipocyte development, we measured KLF14
expression in primary pre-adipocytes isolated from human abdominal
subcutaneous adipose tissue biopsies (female N=4, male N=4) during
proliferation and subsequent differentiation over 14 days. Adipocyte
expression of KLF14 was higher in females compared to males at all time-
points (Figure 3b), demonstrating that the sex-differential expression of
KLF14 observed in adult biopsies is present throughout adipogenesis.
We next investigated the link between reduced KLF14 expression and
adipocyte development. Compared to tissue from non-risk allele
homozygotes, fresh adipose tissue explants from female risk allele
homozygotes showed a 44% reduction (P=0.001, N=132) in lipogenesis as
measured by the incorporation of 14C- glucose label into the triacylglycerol
backbone (Figure 5e). There was no significant difference in males (P=0.49,
N=32) (Figure 5e). We confirmed these findings in vitro through shRNA
knockdown (40% at day 1 and 33% at day 14) of KLF14 (Figure 5a) in
primary pre-adipocytes isolated from abdominal subcutaneous biopsies (N=7
females): this resulted in 60% reduction in TAG accumulation after 14 days of
differentiation (P=0.03) (Figure 5c). The adipocyte differentiation wholly relies
on de novo lipogenesis as the cell culture medium contains glucose but not
fatty acids. Knowing that SLC2A4 (which encodes GLUT4) is a KLF14
transgene, we first tested the expression of GLUT4 in the KLF14 shRNA
differentiated adipocytes. This showed prominent reduction (by 64±7%
(P=0.02)) (Figure 5a). To investigate the functional consequences of the
reduction in GLUT4 expression, we quantified the insulin-stimulated glucose
uptake, finding a 50% reduction in KLF14 shRNA differentiated adipocytes
(Figure 5d). Concomitant with the lower glucose uptake and lipogenesis, the
expression of adipocyte maturation factors PLIN1 (-42%±8, P=0.02) LEP (-
54%±13, P=0.03), and FITM2 (-12%±4, P=0.04) was significantly ablated in
the knockdown cells, whilst the levels of the classical early-differentiation, pro-
adipogenic transcription factors (CEBPA, PPARG2) were not changed
(Figure 5a). KLF14 knockdown also increased cellular proliferation, observed
as reduced doubling time (P=0.02) (Figure 5b). We infer that reduced levels
of KLF14 result in a defect in glucose uptake resulting in impaired adipocyte
lipogenesis and maturation, and propose that the increase in proliferation
results from fruitless cycling at earlier stages of differentiation.
Adipocyte size is an important marker of adipose tissue dysfunction and
metabolic disease and, in some studies, has been predictive of insulin
resistance and T2D independent of obesity36-40. We assessed adipocyte size
and cell number distribution by histological analysis of subcutaneous
abdominal and gluteal adipose tissue biopsies from sex-, age- and BMI-
matched pairs of individuals from the Oxford Biobank, homozygous for either
the risk or non-risk haplotypes (N=18 males, 18 females). At both sites, there
was a marked shift towards increased adipocyte size in T2D-risk haplotype
homozygotes: this was only observed in women (comparison of medians:
abdominal P=0.008, gluteal P=0.02) (Figure 6b,d,e; Supplementary Figure
6a,b,c). We estimated, assuming spherical cell morphology, that there was a
two-fold difference in adipocyte volume between the genotypic groups in
females. Gluteal and abdominal tissue from female T2D-risk haplotype
homozygotes also contained fewer total adipocytes (comparison of medians:
Abdominal TT=2.21±0.31x1010, GG=0.66±0.19x1010, P=0.04; Gluteal
TT=4.87±0.93x1010, GG=2.25±0.58x1010, P=0.04). The cell size findings and
their sex-specificity were confirmed using a different technique (measuring
diameter of isolated adipocytes from collagenase digested tissue) in an
independent cohort of 28 females (P=0.004), and 16 males (P=0.78) also
matched for age and BMI (Figure 6c).
DISCUSSION
T2D risk variants that lead to reduced expression of KLF14 in adult adipose
tissue are therefore also implicated in a defect of adipogenesis that is likely to
reflect impaired glucose uptake. The consequence of this defect appears to
be a profound effect on subcutaneous adipose tissue structure characterised
by the presence of fewer but larger adipocytes. We infer that KLF14 risk-allele
carriers are obliged to favour expansion of existing adipocytes to meet lipid
storage needs, resulting in suboptimal fat storage and an increased risk of
insulin resistance and T2D. This hypothesis of impaired fat storage is
consistent with the elevated circulating triglyceride levels observed in KLF14
risk haplotype carriers. Reduced expression of KLF14 in female carriers of the
risk-allele is likely to drive a shift in the distribution of adipose tissue between
subcutaneous fat depots, favouring abdominal over gluteal deposition. This
results in loss of the relative protection against the metabolic consequences of
adipose tissue accumulation associated with adipose deposition in gynoid
sites which has been widely observed in epidemiological studies41,42 and is
consistent with the observed association of the KLF14 T2D-risk allele and
human fat distribution.
We note that the sex-specificity of the KLF14 risk alleles varies across
biological domains: effects on adipocyte development and whole body
phenotypes are more marked in females despite the fact that cis and trans
regulatory effects are shared between the sexes. The simplest explanation for
this discordance is a threshold effect driven by the higher baseline expression
levels of KLF14 in females, though it is also possible that males lack
downstream processes (e.g. related to hormonal environment) that mediate
the response to KLF14. While the KLF14 T2D association was discovered
through typical GWAS approaches, the remarkable specificity of this
association – with respect to sex, parent of origin, ethnicity and tissue of
action - is a reminder that risk prediction, or targeted medical treatment,
based on genotype alone may fail to capture highly-relevant aspects of
biological complexity.
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Figure Legends
Figure 1 |Cell-type-specific enhancer in the risk haplotype regulates KLF14
expression. Association of KLF14 locus variants with (a) type 2 diabetes (N=69,033)
(Morris et al39), (b) high density lipoprotein levels (N=99,900) (Teslovich et al27); (c)
KLF14 mRNA abundance in adipose tissue of 776 women (TwinsUK). Circles
represent genotyped and imputed DNA variants and are colored by LD r2 values with
the index SNP rs4731702. The red asterisk indicates the position of methylation
probe cg02385110. Association between genotype and KLF14 expression was
assessed using mixed effects models, correcting for family structure and relevant
covariates (methods). Uncorrected P-values displayed. (d) Chromatin state
annotations for the locus across 93 reference epigenomes (rows) for cell and tissue
types profiled by the Roadmap Epigenomics and ENCODE Projects. Colors
correspond to chromatin states; yellow=enhancer, red=promoter as detailed in Ernst
et al43. ESC, embryonic stem cell; HSC, hematopoietic stem cell; iPSC, induced
pluripotent stem cell. Blue box contains the putative enhancer. Chromosome
coordinates correspond to UCSC Genome Browser build hg19. (e-i) Boxplots of KLF14
mRNA abundance (e-f) and methylation of probe cg02385110 (g-i) in concurrently-
sampled adipose (NExpression=720; NMethylation=595), skin (NExpression=606; NMethylation=414) and
whole blood (NExpression=368; NMethylation=289) from the TwinsUK study participants, based
on rs4731702 genotype (CC=risk-allele homozygotes). KLF14 expression was
undetectable in whole blood. Boxplots display the median, with hinges
corresponding to the first and third quartiles. Whiskers extend from the hinge to the
largest value no further than 1.5xinter-quartile range, with values beyond shown as
outliers. Associations assessed using linear regression, correcting for family structure
and relevant covariates (methods).
Figure 2 | KLF14 cis-eQTL is an adipose-specific trans-regulator of a large network
of genes. a, Genomic location of the 385 trans-genes. Line colour indicates direction
of trans-effect; blue, positive association with T2D risk-allele; green, negative. b, 177
trans-genes are enriched for KLF14 motifs and 18 trans-genes form a sub-network
regulated by SREBF1. Genes are colored as in a) to indicate direction of trans-effect.
Solid lines link KLF14 to trans genes containing KLF14 binding sites, dashed lines link
SREBF1 to trans-genes containing SREBF1 binding sites c, KLF14 trans-network
replicates in three independent adipose cohorts, METSIM (N=770), MGH (N=701)
and deCODE (N=589). Histograms show p-value distribution of trans-genes in each
replication cohort. d, Trans-network is not present in other tissues in the same
TwinsUK samples as adipose discovery. Histograms show P-value distribution of
trans-genes in skin (N=716), LCLs (N=814), and whole blood (N=384). In TwinsUK,
METSIM and DeCODE, association between KLF14 lead SNP rs4731702 genotype and
gene expression was assessed using linear models with correction for relevant
covariates (see methods), and using the Kruskal-Wallis test in the MGH dataset.
Uncorrected P-values displayed. Trans-gene associations were considered replicated
at P<0.05.
Figure 3 | KLF14 expression is sex-differentiated in biopsies and throughout
adipocyte differentiation. a, Adipose expression of KLF14 in the deCODE cohort. The
KLF14 cis-eQTL has a similar effect size in males (N=265) and females (N=376), but
KLF14 expression is higher in females than males across all genotype classes. Plots
display KLF14 mean relative expression ±SEM. b, Pre-adipocytes derived from
abdominal biopsies and subjected to a 14 day-differentiation protocol show higher
KLF14 expression in females (N=4, mean±SEM) compared to males (N=4,
mean±SEM) at all time points.
Figure 4 | Adipose-specific knockout of Klf14 in the mouse. Clinical chemistry
parameters were measured in female and male adipose-specific (Adipoq-Cre)
knockout (KO) C57BL/6J Klf14 mice and their Adipoq-Cre-expressing, wildtype (Wt)
controls. Mice were fed a standard diet throughout their lifetimes. a, HDL-C at 16
weeks significantly reduced in female KO group mice compared to wildtype (P=
0.04); b, TG at 16 weeks significantly increased in the male KO group compared to
wildtype (P=0.03 unpaired two-tailed t-test); c and d, glucose levels in an IPGTT at 12
weeks of age significantly increased in female (c) and male (d) KO compared to
wildtype controls at multiple time-points; e and f, in an ITT at 12 weeks of age
glucose reduced to a lesser extent in KO mice compared to their wildtype controls at
multiple time-points in both females (e) and males (f). Pairwise significance as
compared to controls is shown. Analysis in (a) and (b) use unpaired two-tailed t-test
(for male HDL-C, with Welch’s correction), and in (c) to (f) by 2-way ANOVA with
repeated measures and Bonferroni correction (GraphPad Prism 6). Wildtype mice
shown as blue lines and fill, females (N=8) and males (N=8). Adipose KO mice shown
in red lines and fill, females (N=5) and males (N=6). All error bars are plotted as a
mean central value plus or minus the standard deviation.
Figure 5| KLF14 expression effects expression of adipocyte maturation marker
genes and adipocyte function. a, The mean fold change in expression of marker
genes following KLF14 shRNA knockdown. Mean fold change is plotted as the
expression of the labeled gene in KLF14 shRNA adipocytes divided by expression in
control adipocytes. Expression of all genes was measured with Real Time PCR in
seven paired knockdown/control replicates (N=7 ±SEM). A significant decrease in
expression was seen for KLF14, measured at days 1 and 14. There was no change in
early differentiation markers PPARG2 and CEBPA at either day 1 or 14. A significant
decrease in expression was seen for late-stage differentiation markers LEPand PLIN1
and late-stage adipogenic trans-genes FITM2 and GLUT4 at day 14. Statistical
significance was assessed using a Wilcoxon signed-rank two-sided test. (* ) marks
statistical differences between knockdown and control adipocytes for each gene (p≤
0.05). b, KLF14 shRNA pre-adipocytes isolated from female abdominal adipose
tissue biopsies (N=7, mean±SEM) have a significant decrease in doubling time
compared to non-target shRNA controls. c, KLF14 shRNA differentiated adipocytes
have a significant decrease in TAG accumulation (N=7, mean±SEM) and d, in insulin
stimulated glucose uptake (N=6, mean±SEM) compared to non-target shRNA
controls. Statistical significance was assessed using a Wilcoxon signed-rank two-
sided test. e, Female KLF14 risk allele homozygotes (CC) have a significant decrease
in lipogenesis, as measured in adipose explants, compared to non-risk allele
homozygotes (TT) (Female (N=132), Male (N=32), mean±SEM). The minimum and
maximum values of lipogenesis are presented with their whiskers. The line in the box
represents the median. Statistical significance was assessed using unpaired two-
sided t-test.
Figure 6 | Adipose tissue of Type 2 diabetes risk allele homozygotes contains
fewer, larger mature adipocytes compared to non-risk allele homozygotes. a,
Sections of subcutaneous abdominal adipose tissue biopsies from two age- and BMI-
matched female volunteers. Histological sections were stained with hematoxylin and
eosin. b, The minimum and maximum values of adipocyte cell surface area in
abdominal adipose histological sections stratified by sex and genotype are presented
with their whiskers. The line in the box represents the median. >100 cells were
measured for each biopsy (N=18 per sex). Statistical significance was assessed using
a Wilcoxon signed-rank two-sided test. c, The minimum and maximum values
ofadipocyte cell volume measured in dispersed adipocytes from collagenase-
dispersed abdominal adipose tissue stratified by sex and genotype are presented
with their whiskers (female N=28, male N=16, mean ± SEM). The line in the box
represents the median. Statistical significance was assessed using a Wilcoxon
signed-rank two-sided test. d, Cumulative frequency distribution of adipocyte cell
surface area in females (N=18), measured as in b. e, Cumulative frequency
distribution of adipocyte cell surface area in males (N=18), measured as in b.
Tables
Trait Type 2 diabetes Fastinginsulin
Fasting
glucose HDL TG LDL BMI WHR Waist Hip
GWAS Citation Morris, 2012 Horikoshi,2015
Horikoshi,
2015
Teslovich,
2010
Teslovich,
2010
Teslovich,
2010
Locke,
2015
Shungin
2015
Shungin,
2015
Shungin,
2015
Sex-
combined
β 1.10 (1.06-1.15) 0.019 0.007 -0.015 0.016 0.009 0.009 0.006 -0.009 -0.017
P 3.6x10-8 1.2 x10-5 0.07 1.2x10-15 1.1 x10-6 0.02 0.002 0.08 0.009 1.6 x10-6
N 69,033 24,243 46,656 99,900 96,598 95,454 322,022 212,127 230,394 211,022
Female
β 1.14 (1.08-1.20) 0.031 0.011 -0.042 0.036 0.018 0.010 0.021 -0.008 -0.033
P 1.4x10-6 2.4 x10-7 0.07 3.5 x10-11 1.0 x10-8 0.002 0.01 3.6 x10-6 0.08 9.9 x10-14
N 40,413 13,073 23,663 62,816 59,473 61,803 171,899 117,967 126,971 117,288
Male
β 1.08 (1.03-1.14) 0.006 0.004 -0.034 0.013 0.010 0.009 0.011 -0.009 0.003
P 0.003 0.36 0.58 9.9 x10-7 0.04 0.19 0.03 0.02 0.04 0.50
N 28,620 11,158 17,731 37,745 35,288 36,840 152,830 94,344 103,616 93,919
Table 1 | rs4731702 is associated with insulin resistance, lipid and body-
composition phenotypes HDL, high density lipoprotein; TG, Triglycerides; LDL, low
density lipoprotein; BMI, body mass index; WHR, waist-hip ratio. Morris et al30
results are taken from the Stage 1 Discovery as Stage 2 included non-European
samples. HDL and LDL effect sizes are reported in mmol/l, TG was log-transformed.
Type 2 Diabetes effect sizes are Odds Ratios, not Betas.
Online Methods
Choice of lead SNP
The T2D association at the KLF14 locus consists of 29 SNPs in near perfect
linkage disequilibrium (r2>0.94). The lead SNP in T2D GWAS has been
reported as rs4731702 (Kong, et al1) rs972283 (Voight, et al2) and rs10954284
(Morris et al30 and Mahajan, et al15), all three of which are in perfect linkage
disequilibrium in Europeans (r2=1). The lead SNP for the HDL GWAS is
rs4731702 (Teslovich et al28, Willer et al27). As rs4731702 is present on all
commonly used genotyping arrays we chose to report all results in this
manuscript with respect to rs4731702, where C is the T2D risk allele and T is
the non-risk allele.
TwinsUK gene expression
Biopsies and blood samples from 856 healthy female twins from the TwinsUK
cohort were collected within the MuTHER project44 and RNA sequenced as
previously described7. See Supplementary Note for further details of the
TwinsUK data.
Cis and trans eQTL analysis
Cis and trans eQTL analysis was conducted in the TwinsUK RNAseq data as
follows. Exon read counts were corrected for technical covariates and family
structure using a mixed effects model including insert size and mean GC
content as fixed effects and primer index, sample processing date, family and
zygosity as random effects. Corrected residuals were used for all eQTL
analyses. Cis- and trans-eQTL associations were conducted using the
MatrixeQTL package45 using a standard additive linear model, with BMI, age
and age-squared included as covariates. A window size of 1Mb was used for
cis-eQTL analyses. A FDR46 threshold of 5% was applied to trans-eQTL
results, with FDR calculated using the qvalue package47 in R version 3.1.1.
The deCODE, METSIM and MGH cohorts were analyzed as previously
described8-10.
Functional fine mapping
We used the chromatin states predicted by ChromHMM43 utilizing 127
reference epigenomes from the ENCODE16 and Roadmap Epigenomics
projects55. ChromHMM segments the genome into 15 states using 5 chromatin
marks (H3K4me3, H3K4me1, H3K36me3, H3K27me3, H3K9me3) with
predictions ranging from active transcription start sites to repressed Polycomb
complexes. The ChromHMM predicted enhancer spans a 1.6 kb region, ~4kb
upstream of KLF14 transcription start site (TSS) and harbors 5 of the T2D
GWAS SNPs (rs12154627, rs6973807, rs6974400, rs6974288, rs11762784).
TwinsUK methylation data
Adipose tissue sample in 603 individuals (taken from the same biopsy as the
RNAseq data) and 309 whole blood samples from the TwinsUK study were
profiled on the Illumina Infinium HumanMethylation450 BeadChip
previously48,49. The following covariates were included in analyses, batch
(beadchip), BS conversion efficiency (as assessed using the built-in BS
conversion efficiency controls) and BS-treated DNA input. The association of
age with methylation was examined using a linear mixed effect regression
model (LME) adjusting for batch effects, BMI, and, family and zygosity
structure. Blood methylation was additionally corrected for estimated cell
counts. To compare methylation and expression levels, each was first
adjusted for covariates, and Pearson’s correlation performed on the residuals.
Trans-network mediation analysis:
Significant mediation was determined by computing Sobel’s test statistic50. To
calculate the mediation score, the three following models were implemented:
Model 1:
Model 2:
Model 3:
Where Y = trans-gene expression, A = age, E = cis-gene expression, P =
BMI, G = cis-genotype.
By conditioning on cis-gene expression (the mediator: ) we can determine if
each individual association detected in trans is regulated in cis or is
independent by quantifying .
Enrichment of KLF14 Chipseq binding in trans-genes
We utilized the HEK293 KLF14 Chipseq data from Najafabadi et al (2015)51.
Genomic co-ordinates of the peaks of KLF14 binding (along with the summit
position for each peak) identified in the Chip-seq experiments were available
in the supplementary data of Najafabadi et al (2015)
(http://hugheslab.ccbr.utoronto.ca/supplementary-data/C2H2_B1H/). For the
enrichment analysis for KLF14 binding, we utilised the summit position of the
18,652 distinct Chip-seq peaks of KLF14 binding (filtered on a minimum
Phred-like quality score of call confidence of 50) provided in this data. An
enrichment of KLF14 binding sites for the 385 genes with trans-expression
association with the KLF14 locus (FDR < 5%) was evaluated by comparing
the proportion of genes for which KLF14 binding sites were identified in the
following two groups of genes: first, the 385 genes with trans-expression
association with the KLF14 locus; and second, the remaining genes that were
tested in the trans-expression analysis (N=18,678). An enrichment of KLF14
binding sites for the 385 genes with trans-expression association was further
evaluated by performing 10,000 permutations of a random set of 385 genes
sampled from the entire set of genes that was tested in the trans-expression
analysis, and estimating the number of genes with KLF14 binding sites for
each permutation.
iRegulon transcription factor binding analyses
In order to find the KLF14 regulon (a transcription factor (TF) and its direct
transcriptional targets, which contain common TF binding sites in their cis-
regulatory control elements) we use the iRegulon cytoscape plugin52. The
prediction of regulons consists of four steps: 1) motif detection, this process
relies on an offline scoring step of a sequence search space (10kb or 20kb
around the TSS) whereby every gene in the human genome, along with
orthologous sequences in ten other vertebrate genomes, is scanned with
Cluster-Buster53 for homotypic clusters of motifs using a library of nearly
10,000 position weight matrices (PWMs), resulting in a gene-ranking list for
each PWM. Enriched motifs are those motifs for which the input genes are
enriched at the top of the ranking, using the Area Under the Curve (AUC) of
the cumulative curve; 2) Track discovery, this step also relies on an offline
scoring step whereby every gene in the human genome is scored with around
1,120 ChiP-seq tracks, generating a list of TFs according to the highest ChiP
peak within the regulatory space; 3) Motif2TF mapping, the candidate TFs are
prioritized by finding the optimal path from a motif to a TF, in a motif-TF
network; 4) Target detection, for each enriched motif, the candidate targets
are selected as the significantly highly ranked genes compared to the
genomic background and to the entire motif collection as background.
Functional enrichment analysis
KLF14 trans-genes were subdivided into three subsets based on the
presence of bindings motifs for KLF14, SREBF1 or neither. The three subsets
were assessed for functional enrichment using ToppFun, part of the
ToppGene package24. Results were corrected for multiple testing using the
Bonferroni method, with enrichments considered significant at Bonferroni-
corrected P < 0.05.
Overlap between KLF14 trans-regulated genes and published GWAS
results
The NHGRI-EBI GWAS catalog54 (Available at: www.ebi.ac.uk/gwas,
accessed November 2015) was filtered so as to retain signals meeting
genome-wide significance (P<5.0x10-8). Corresponding cis-eQTLs for each of
the 385 KLF14 trans-genes, including secondary, tertiary and quaternary cis-
eQTLs sequentially conditioned on the lead cis-eQTLs at each locus (a total
of 465 cis-eQTLs), were then cross-referenced against the NHGRI GWAS
results, retaining at each KLF14 trans-gene locus those reported NHGRI
associations within +/-250kb of the relevant cis-eQTLs that showed moderate
to high LD (r2≥0.8) between the reported GWAS SNP and the respective cis-
eQTL.
Association between KLF14 expression and TwinsUK metabolic traits
To determine if gene expression was associated to a concurrently measured
phenotype of interest, expression of each exon was treated as a quantitative
trait in a linear mixed effects model implemented using the lme4 package51.
The linear mixed effects model was adjusted for age, BMI and technical
covariates (mean GC content and insert size mode) (fixed effects), family
relationship (twin pairing), primer index and zygosity (random effects).
Phenotypic data were treated as continuous independent traits, and were
inverse normal transformed. A full model with the phenotype fitted was
compared to a null model (no phenotype) using a 1d.f. ANOVA. A FDR was
estimated using the package QVALUE to obtain q-values that correspond to a
controlled FDR 5%. TwinsUK metabolic phenotypes were measured at the
same time-point as the biopsy and were collected as previously described3.
Body-fat distribution traits were measured using dual-energy X-ray
absorptiometry (DXA; Hologic QDR 4500 plus) with the standard protocol.
Trait-Expression Association Enrichment Analyses
The most significantly-associated exon per gene was retained for all genes.
Enrichment was assessed by comparing the number of genes significantly
associated with each phenotype (at q<0.05) within the set of KLF14 trans-
genes (Ntrans-genes=385) to the remaining genes not within the KLF14 trans-
network (Ngenes=18,716), using a Fisher’s exact test.
Sex x SNP interaction analysis in large cohorts
Details of the data preparation, quality control and cohort specific analysis
covariates for the UK Biobank, GERA and WTCCC/T2D data are provided in
the Supplementary Methods. For evaluating the SNP x Sex interaction effect
of rs4731702 on anthropometric traits in the UK Biobank, we tested for
association of the genotype with each inverse normalized variable using linear
regression with a main effect for SNP and SNP-by-sex interaction terms using
an additive model. We adjusted for covariates: age, age2, sex, six (within UK)
ancestry principal components, and array used to measure genotypes. A
maximum of 118,193 individuals (62,165 females and 56,027 males) with
genotype and valid BMI, height, waist and hip were available for analysis. For
evaluating the SNP-by-sex interaction effect of rs4731702 on risk of T2D, we
considered a total of 13,728 T2D cases and 129,911 controls from 3 studies
from populations of European ancestry. Sample and variant quality control
was performed within each study (see Supplementary Methods). Within each
study, the variant was tested for T2D association under an additive model
after adjustment for study-specific covariates, including principal components
to adjust for population structure and with a main effect for SNP and SNP-by-
sex interaction terms. We then combined association summary statistics for
the variant across studies via fixed-effects inverse-variance weighted meta-
analysis.
Animal experiments information
CRISPR-Cas9 mice were generated in the Harvard University Genome
Modification Facility and were kept and studied in accordance with Harvard
University’s Faculty of Arts and Sciences Institutional Animal Care and Use
Committee (IACUC) protocol 14-05-202. Klf14tm1(KOMP)Vlcg mice were kept and
studied in accordance with UK Home Office legislation and local ethical
guidelines issued by the Medical Research Council (Responsibility in the Use
of Animals for Medical Research, July 1993; home office license 30/3146).
Experimental design of in vivo mouse experiments in CRISPR-Cas9
mouse models
The CRISPR-Cas9 knockout mouse models were generated as described in
the Supplementary Note. All procedures used for CRISPR-Cas9 animal
studies were approved by Harvard University’s Faculty of Arts and Sciences
Institutional Animal Care and Use Committee and were consistent with local,
state, and federal regulations as applicable. All animals were housed in a 12-
hour dark-light cycle and fed standard chow ad libitum in conditions similar to
those described above. The control mice and KO mice were littermates from
several litters that were timed to be the same age; the mice were kept in the
same cages, in as few cages as permitted by the restrictions set forth by
institutional policy (typically no more than three adult mice per cage).
For lipid measurements, blood samples were collected from the lateral tail
vein following an overnight fast. Samples were kept on ice then centrifuged for
10 minutes at 2,000xg in a centrifuge at 4°C. The plasma levels of triglyceride,
total cholesterol, and HDL-C were measured using Infinity Triglycerides
Reagent (Thermo Fisher), Infinity Cholesterol Reagent (Thermo Fisher) and
HDL-Cholesterol E (Wako Diagnostics) independently according to the
manufacturers’ instructions. For the intraperitoneal glucose tolerance test
(IPGTT), the mice were fasted overnight, and glucose concentrations were
measured immediately before and at 20, 40, 60, and 120 minutes after
intraperitoneal injection of glucose (1g/kg body weight). For the insulin
tolerance test (ITT), the mice were fasted for 4 hours, and glucose
concentrations were measured immediately before and at 20, 40, 60, and 120
minutes after intraperitoneal injection with human insulin (Sigma) at 1U/kg
body weight. Whole blood glucose levels were measured using a glucose
meter and test strips (OneTouch). For histological examination, fat tissue was
fixed in 4% paraformaldehyde and embedded in paraffin. Consecutive
sections were cut and stained by hematoxylin and eosin for light microscopy
examination and evaluation.
Experimental design of in vivo mouse experiments in deletion mouse
models
Klf14tm1(KOMP)Vlcg deletion mice were generated as described in the Supplemental
Note. Deletion mice were kept under controlled light (light 7am–7pm, dark
7pm–7am), temperature (21±2°C) and humidity (55±10%) conditions. They
had free access to water (9–13 ppm chlorine) and were fed ad libitum on a
commercial diet (SDS Rat and Mouse No. 3 Breeding diet, RM3) until 18
weeks of age when they were then transferred to a high fat diet (45% kcal
from fat; D12451; Research Diets).
Cohorts of male and female mice were bred for longitudinal blood and body
composition based phenotyping tests. These included four groups: 1) MAT
(heterozygotes (hets) inheriting the allele maternally), 2) PAT (hets inheriting
the allele paternally), 3) WT MAT controls and 4) WT PAT controls. Sample
size estimates were based on previous experience and data from other
mouse models in which the relevant traits were measured. These data were
used in power calculations to help in deciding cohort sizes. Mice were housed
in single sex groups of mixed genotype across multiple litters and were not
randomised into groups. Mouse IDs and genotypes were recorded on the
cages and were not blinded to the operator carrying out the animal procedure
although subsequent tests only include animal ID information and clinical
chemistry was carried out by a core service without knowledge of the
genotypes.
Echo-MRI analysis and fasted blood sampling from the lateral tail vein (local
anaesthetic) were carried out at 8, 12, 22 and 27 weeks of age. Whole blood
glucose was measured using an AlphaTRAK meter and test strips (Abbott).
Plasma insulin was assayed using a Mouse insulin ELISA kit (Mercodia).
Terminal blood samples were collected from 33 week old mice by
intraperitoneal anaesthesia and cardiac puncture following an overnight fast.
Samples were kept on ice then centrifuged for 10 minutes at 8,000xg in a
centrifuge set to room temperature. The resulting plasma was analysed on
board a Beckman Coulter AU680 clinical chemistry analyser using reagents
and settings recommended by the manufacturer. Clinical biochemistry for
cholesterol analysis was conducted on 8, 22, 27 and 33 week blood samples.
Statistical analysis of mouse data
Data collection, summary calculations and descriptive statistics were carried
out using Microsoft Excel 2010. Statistical analysis was carried out using
software Graphpad Prism v6. Effects of genotype at different time-points on
clinical chemistry parameters were determined by two way ANOVA with
repeated measures and Bonferroni’s correction for multiple comparisons.
Unpaired 2-tailed t tests were used for pairwise comparisons as appropriate
and variances were equal, other than in the case of figure 4a male data where
a Welch’s correction was applied for unequal variance. Data sets were tested
for normal distribution and equal variance according to a D'Agostino-Pearson
omnibus K2 normality test and a Brown-Forsythe test respectively in Graphpad
Prism. Consequently, non-parametric tests were applied as necessary and
indicated in the figures. In these cases area under the curve was calculated
(baselined to t=0 values) and tested with either a 1-way ANOVA Kruskal-
Wallis test and Dunns multiple comparison test where there were multiple
groups (Klf14tm1(KOMP)Vlcg knockout mice) or Mann-Whitney 2-tailed t-test when
there were only two groups (CRISPR-Cas KO). Further as indicated,
individual pairwise comparisons were made using Mann-Whitney 2-tailed t-
tests and shown in the figures.
Gene expression in mouse models
Mouse RNAseq data from was collected as described in the Supplemental
Note and analysed by the in house bioinformatics team at MRC Harwell using
a previously described pipeline55. Functional enrichment of mouse
differentially expressed genes was assessed using ToppFun24, with
enrichments considered significant after FDR multiple testing correction
(q<0.05). MEME_chip55 was used to identify motifs that were significantly
over-represented in DNase1 hypersensitivity hotspots upstream of mouse
differentiated genes.
Isolation, culture, and differentiation of pre-adipocytes
Abdominal subcutaneous adipose tissue (ASAT) biopsies were obtained from
8 healthy subjects (four females and four males) recruited from the Oxford
BioBank (OBB) (http://www.oxfordbiobank.org.uk), aged 30-50 years with BMI
ranging from 22-27kg/m2. The study was approved by Oxfordshire Clinical
Research Ethics Committee (08/H0606/107+5) and all subjects gave written
informed consent. Primary pre-adipocytes were isolated as previously
described (Collins et al56) and cultured in DMEM/F12 Ham nutrient mixture
(DMEM/F12), 10% FBS, 2 mmol/L glutamine, 0.25 ng/mL fibroblast growth
factor, 100 units/mL penicillin, and 0.1 mg/mL streptomycin. Confluent pre-
adipocytes were then stimulated for 14 days with an adipogenic cocktail
comprising DMEM/F12, 2mmol/L glutamine, 17mmol/L pantothenate,
100nmol/L human insulin, 10nmol/L triiodo-L-thyronine, 33mmol/L biotin,
10mg/mL transferrin, 1mmol/L dexamethasone, 100 units/mL penicillin, and
0.1mg/mL streptomycin. For the first 4 days, 0.25mmol/L 3-isobutyl-1-
methylxanthine and 4mmol/L troglitazone were added. The cells were
harvested every day during proliferation and 14 days during differentiation.
RNA isolation and Real-time PCR in pre-adipocytes
Total RNA was extracted from pre-adipocytes as described by Collins et al56.
Real time PCR was performed on an Applied Biosystems 7900HT, using
TaqMan Assays-on-Demand (Applied Biosystems) and Klear Kall Master Mix
(KBiosciences). mRNA expression values for target genes were calculated
using the DCt transformation method57. The DCt was calculated as follows:
DCt = efficiency (minimum Ct–sample Ct). Values were normalized to
endogenous control genes (PPIA and UBC)58.
Explant lipogenesis experiments
Adipocytes isolated from abdominal subcutaneous adipose tissue were used
to measure activation of insulin-stimulated lipogenesis, as described in detail
elsewhere59. In brief, isolated human adipocytes were incubated at a
concentration of 2% (v/v) in Krebs–Ringer phosphate buffer (pH 7.4)
containing albumin (40mg/ml), [3-3H] glucose (5×105dpm/ml), unlabelled
glucose (1μmol/l) and varying concentrations of human insulin (0-70nmol/l).
The incubations were conducted for 2 h at 37°C with air as the gas phase.
Incubations were stopped by rapidly chilling the incubation vials to 4°C and
the incorporation of radiolabelled glucose into adipocyte lipids (i.e.
lipogenesis) was determined. Lipogenesis was expressed as the amount of
glucose incorporated either per lipid weight of fat cells or per fat cell number,
as described previously59.
Short Hairpin RNA–Mediated Silencing of KLF14
KLF14 was silenced in primary pre-adipocytes derived from female ASAT.
Lentiviral particles were produced by transient co-transfection of HEK293
cells, using KLF14-short hairpin RNA (shRNA) lentiviral transduction construct
(SHCLNV-NM_138693.1-255s1c1; Sigma-Aldrich) and non-target shRNA
lentiviral constructs (SHC002V; Sigma-Aldrich) with packaging vectors
(MISSION [Sigma-Aldrich]). Cells were stably transfected by transduction of
pre-adipocytes with lentiviral particles followed by selection in growth media
containing 2mg/ml puromycin.
Quantification of intracellular lipid content
Control and KLF14 shRNA cell lysates were prepared in lysis buffer
containing 1% IGEPAL-630, 150mM NaCl and 50mM Tris HCl. Lysates were
sonicated and an aliquot was collected for protein quantification using the
BioRad Dc Protein Assay kit. The remaining lysate was heated at 95°C for 30
minutes, allowed to cool to room temperature, and then centrifuged at
12,000xg for 10 minutes. Triacylglycerol concentration in the supernatant was
determined using a commercially available enzymatic kit (Instrumentation
Laboratory UK) on an iLAB 650 Chemistry Analyser. Total triacylglycerol was
normalised to protein concentration.
Estimation of Cell Doubling Time
Equal number of control and KLF14 shRNA cells were seeded in T75 flasks,
1.5x105 cells. Cells were trypsinized and double counted every 5 days.
Doubling time was calculated using the formula Td= (t2−t1)×[log(2) ÷ log(q2 ÷
q1)], where t = time (days) and q = cell number.
Insulin stimulated glucose uptake
Glucose uptake was assayed according to the established protocol from a
commercial glucose uptake kit (J1342; Promega). The luminescent glucose
uptake assay was applied to control and KLF14 shRNA differentiated
adipocytes in 96-well plates. In brief, differentiated cells were starved in
hormones-free DMEM/F12 medium overnight. The medium was removed and
the cells were washed with 100μl of phosphate-buffered saline (PBS) followed
with 10nM insulin incubation for 1h at 37°C in 5%CO2. To initiate glucose
uptake, 50μl of 2DG (1mM) in PBS was added to the cells. The uptake
reaction was stopped, and the samples were processed as described in the
protocol. All assay steps were performed at room temperature. All data were
acquired on a PerkinElmer EnSpire 2300 multimode plate reader instrument,
with an integration time of 0.5s.
Adipocyte Cell Size and Number Study Population and Sample
Collection
Nine females and 9 males carrying KLF14 risk allele and paired control
subjects age (30-50) and BMI (22-27kgm-2) matched were recruited from the
OBB. Paired abdominal and gluteal subcutaneous adipose specimens were
obtained by gun and needle biopsies. The gun biopsies were fixed in 10%
paraformaldehyde, embedded in paraffin wax, cut into 5 µm sections, and
stained with hematoxylin and eosin. Sections were viewed at 20x
magnification, and adipocyte cross-sectional area was calculated using Adobe
Photoshop 5.0.1 (Adobe Systems, San Jose, CA) and Image Processing Tool
Kit (Reindeer Games, Gainesville, FL). As previously described60, in order to
accurately determine the minimum number of cells required for measurement
of cell size distribution in a sample, we took 4 samples and counted 1,000
cells in each. Data were removed by 100 at a time and it was observed that
the coefficient of variation started to increase when fewer than 100 cells were
included in each biopsy. Therefore, we included only biopsies with more than
100 cells available for quantification (N=9 pairs from each genotype).
Statistical significance was assessed using a Wilcoxon signed-rank test.
Replication of the cell size was undertaken in a Swedish cohort61. Abdominal
subcutaneous adipose specimens were obtained by needle biopsy.
Adipocytes were separated from stroma cells by treatment in a shaking bath
at 37°C for 60 min with collagenase (0.5mg/L) in 5ml Krebs Ringer phosphate
buffer (pH7.4) with purified BSA (40g/L) as previously described59. Adipocyte
suspensions were then rinsed three times in collagenase-free buffer using
nylon filters, and the cell sizes were measured by direct microscopy. The
mean adipocyte diameter was calculated from measurements of 100 cells and
statistical significance assessed using a Wilcoxon signed-rank test. Cell
numbers were calculated using the formula described by Hirsch, et al62 where
DXA measured adipose depot size was divided by mean cell volume.
Date Availability Statement
TwinsUK RNAseq data is available from EGA (Accession number:
EGAS00001000805). TwinsUK adipose methylation data is available from
ArrayExpress (E-MTAB-1866), and blood methylation data from GEO
(GSE50660). TwinsUK genotypes are available upon application to the
TwinsUK cohort. METSIM adipose array data is available from
GEO(GSE70353).
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Supplementary Figure 1 
Sex-stratified	and	parent	of	origin	effects	on	the	KLF14		trans-	eQTL.			
QQ-plots	of	association	between	rs473102	and	all	adipose	probes	in	the	deCODE	dataset	(female	N=376	and	male	N=265).	Top	row	displays	results	
from	standard	genotypic	tests,	bottom	row	displays	results	for	test	of	association	to	maternally	inherited	allele.	
 
 
 
Supplementary Figure 2 
Geographic	distribution	of	rs4731702	in	the	Human	Genome	Diversity	Panel.	
The	ancestral	T2D	risk	allele	C	is	colored	in	orange,	the	derived	allele	T	in	blue.	Figure	generated	from	the	HGDP	Selection	Browser	at	the	Pritchard	
Lab	(http://hgdp.uchicago.edu/cgi-bin/gbrowse/HGDP/).	rs4731702	does	not	display	evidence	of	positive	selection	in	the	HGDP	–	with	global	FST	in	
the	80th	percentile	genome-wide	and	non-significant	iHS	and	XP-EHH	scores	in	all	populations71.	Tests	for	recent	positive	selection	at	rs4731702	in	
samples	 from	 the	 United	 Kingdom	 using	 the	 Singleton	 Density	 Score	 (SDS)	 were	 not	 significant	 (P=0.20),	 but	 the	 trend	 was	 towards	 a	 recent	
increase	of	the	non-risk	allele	T72.	By	contrast,	the	KLF14	transcript	does	exhibit	evidence	of	intolerance	to	variation	in	the	ExAC	exome	aggregation	
dataset73	(ExAC	constraint	scores:	Missense	z=	2.32;	Synonymous	z	=	2.41)	suggesting	coding	changes	in	KLF14	are	under	purifying	selection.			
 
 
 
Supplementary Figure 3 
Distinct	450K	methylation	probes	at	the	KLF14	locus	are	associated	to	rs4731702	vs	age	
Figure	shows	results	for	two	450K	probes	assayed	in	the	TwinsUK	adipose	samples	(N=603).	cg02385110,	which	is	~3KB	upstream	of	KLF14	is	shown	
on	 the	 left,	 cg08097417	 which	 is	 at	 the	 KLF14	 transcription	 start	 site	 is	 shown	 on	 the	 right.	 The	 beta	 distributions	 (top	 row),	 association	 to	
rs4731702	(T2D	risk	allele	homozygotes	=	2)	(middle	row)	and	association	to	age	(bottom	row)	differ	between	the	two	probes.	cg02385110	has	a	
higher	mean	beta	value,	is	associated	to	rs4731702	(P=2.1x10-7),	and	is	not	associated	to	age	(P=0.64).	In	contrast,	cg08097417	is	not	associated	to	
rs4731702	 (P=0.99)	 but	 is	 highly	 associated	 to	 age	 (P=3.6x10-61).	 Associations	were	 tested	with	 linear	mixed	 effect	models	 adjusting	 for	 batch	
effects,	BMI	and	famlly	structure.		
 
 
 
 
 
Supplementary Figure 4 
Clinical	chemistry	analysis	of	heterozygous	Klf14tm1(KOMP)Vlcg	knockout	mice	
Clinical	 chemistry	parameters	were	measured	 in	male	knockout	C57BL/6N	 Klf14	mice	and	 their	wildtype	controls.	 Since	Klf14	 is	mono-allelically	
maternally	 expressed	 in	 mouse	 and	 human,	 we	 compared	 heterozygous	 mice	 that	 had	 inherited	 the	 deletion	 allele	 from	 their	 mother	
(heterozygous-MAT,	expressing	the	deletion)	with	heterozygous	mice	that	had	inherited	the	deletion	allele	from	their	father	(heterozygous-PAT,	
not	 expressing	 the	 deletion).	 We	 also	 compared	 the	 two	 groups	 to	 their	 own	 homozygous	 wildtype	 colonymate	 controls	 (wildtype-MAT	 and	
wildtype-PAT).	This	was	because	we	used	two	separate	crosses	to	produce	the	MAT	and	PAT	carrier	cohorts;	one	stock	from	heterozygous	mothers	
and	one	from	heterozygous	fathers,	each	crossed	to	wildytpe	C57BL/6N	mice.	Mice	were	fed	a	standard	diet	and	then	switched	at	18-weeks	of	age	
to	a	45kcal%	high	fat	diet.	Comparing	across	the	timecourses	for	(a),	HDL-C;	(b),	insulin;	(c),	glucose;	(d),	IPGTT	by	calculating	area	under	the	curve,	
base-lined	to	t=0	values	(data	not	shown),	and	analysing	with	a	1-way	ANOVA	non-parametric	Kruskal-Wallis	test	and	Dunns	multiple	comparison	
test	we	found:	that	HDL-C	(a)	was	lower	in	MAT	compared	to	either	PAT	or	wildtype-MAT	(p=	0.0055	and	0.0086	respectively)	and	that	wildtype-
PAT	 compared	 to	 PAT	was	 not	 significantly	 (p=0.56)	 different;	 that	 insulin	 (b)	was	 lower	 in	MAT	 compared	 to	 either	 PAT	 or	wildtype-MAT	 (p=	
<0.0003	and	0.0020	respectively)	and	that	wildtype-PAT	compared	to	PAT	was	not	significantly	 (p>0.99)	different;	 that	Glucose	 (c)	was	 lower	 in	
MAT	 compared	 to	 PAT	 (p=	 <0.0001)	 and	 that	 wildtype–MAT	 and	 wildtype-PAT	 compared	 to	MAT	 and	 PAT	 respectively	 were	 not	 significantly	
(p=0.79	and	>0.99	respectively)	different;	and	that	 for	an	 IPGTT	 (d)	none	of	 the	group	comparisons	were	significantly	different	 (p>0.99)	 to	each	
other.	Then	to	examine	effects	at	specific	times	for	(a)	HDL-C,	(b)	insulin,	(c)	glucose	and	(d)	 IPGTT	individual	pairwise	comparisons	were	made	at	
each	 timepoint	using	a	Mann-Whitney	2-tailed	 t-test	 and	were	 significantly	 reduced	 in	 the	MAT	group	compared	 to	PAT	group	at	8,	22	and	27	
weeks	in	(a,b,c)	and	at	all	timepoints	in	(d).	The	MAT	groups	were	also	significantly	lower	compared	to	wildtype-MAT	for	HDL-C	and	insulin	at	22	
and	27	weeks.	Values	are	expressed	as	mean	±	SD	and	in	(a,b,c)	wildtype-MAT	n=16,	wildtype-PAT	n=9,	heterozygous-MAT	n=15,	heterozygous-PAT	
n=16	and	in	(d)	wildtype-MAT	n	=19,	wildtype-PAT	n=10,	MAT	n=16,	PAT	n=16.	For	(e),	HDL-C;	(f),	LDL-C	and	(g),	total	cholesterol	was	measured	in	
a	33-week	blood	sample	collected	under	terminal	anaesthetic	and	was	significantly,	using	an	unpaired	2-tailed	t-test,	reduced	in	heterozygous-MAT	
mice	compared	to	PAT	mice.	Values	are	expressed	as	mean	±	SD	(PAT	N	=8,	MAT	N	=8).	Wildtype	MAT	grey,	wildtype	PAT	black,	MAT	KO	red,	PAT	
KO	blue	lines	and	fill. 
 
 
 
 
 
Supplementary Figure 5 
Clinical	chemistry	and	histological	analyses	of	global	CRISPR-Cas9	KO	mice	
Clinical	chemistry	parameters	were	measured	in	female	and	male	CRISPR-Cas9	knockout	(KO)	C57BL/6J	Klf14	mice	and	their	wildtype	(Wt)	controls.	
Mice	were	 fed	 a	 standard	 diet	 throughout	 their	 lifetimes.	 (a),	 HDL-C	 at	 12	weeks	 of	 age	was	 significantly	 reduced	 in	 female	 and	 reduced	with	
borderline	significance	in	male	(unpaired	two-tailed	t-test).	(b),	triglycerides	at	12	weeks	of	age	were	not	significantly	different	in	females	or	males	
(unpaired	two-tailed	t-test).	Comparing	across	the	IPGTT	timecourses	(c	and	d)	by	calculating	area	under	the	curve,	base-lined	to	t=0	values,	(data	
not	 shown)	 and	analysing	using	 a	Mann-Whitney	 two-tailed	 t-test	 showed	 there	was	no	 significant	difference	between	male	or	 female	KO	and	
wildtype	mice	 (p=0.23	 and	 0.93	 respectively).	 Then	 in	 order	 to	make	 comparisons	 at	 each	 timepoint	 for	 (c	 and	 d),	 individual	 pairwise	Mann-
Whitney	2-tailed	 t-tests	were	 carried	out,	 and	as	 for	AUC	no	differences	were	 found	 in	 the	 female	data,	 although	 in	males	glucose	 levels	were	
nominally	higher	at	20,	60	and	120	minutes	of	the	test.	(e	and	f),	ITT	at	16	weeks	was	not	significantly	changed	between	wildtype	and	KO	groups	of	
either	female	(e)	or	male	(f)	mice,	analysed	by	2-way	ANOVA	with	repeated	measures	and	Bonferroni	correction.	Values	are	expressed	as	mean	±	
SD	and	in	(a,b)	female	wildtype	n=9,	female	KO	n=9,	male	Wt	n=9,	male	KO	n=9	and	in	(c,d,ef)	female	wildtype	n=9,	female	KO	n=8,	male	Wt	n=9,	
male	KO	N=9.	Wildtype	mice	in	blue	lines	and	fill,	KO	mice	in	red	lines	and	fill.	
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Supplementary Figure 6 
Gluteal	adipose	tissue	of	T2D	risk	allele	homozygotes	contains	fewer,	larger	mature	adipocytes	compared	to	non-risk	allele	homozygotes.	
Adipocyte	cell	area	in	histological	sections	of	subcutaneous	gluteal	adipose	biopsies	from	the	Oxford	BioBank.		a,	Median	cell	area	in	female	(N=18,	
mean	±	SEM)	and	male	(N=18,	mean	±	SEM)	gluteal	biopsies	stratified	by	genotype	at	rs4731702.	b,	Cumulative	frequency	distribution	of	adipocyte	
cell	area	in	females	(N=18).	c,	Cumulative	frequency	distribution	of	adipocyte	cell	area	in	males	(N=18).	Statistical	significance	was	assessed	using	a	
Wilcoxon	signed-rank	two-sided	test.		
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Supplementary	Note	
	
Natural	selection	at	KLF14	
	
Despite	 the	 geographic	 range	 in	 allele	 frequency,	 rs4731702	 does	 not	 display	
evidence	 of	 positive	 selection	 by	 several	 tests.	 	 rs4731702	 	 is	 not	 under	 positive	
selection	in	the	Human	Genome	Diversity	Panel	(HGDP)	–	with	global	FST	in	the	80th	
percentile	 genome-wide	 and	 non-significant	 iHS	 and	 XP-EHH	 scores	 in	 all	
populations1.	 Tests	 for	 recent	 positive	 selection	 at	 rs4731702	 in	 samples	 from	 the	
United	 Kingdom	 using	 the	 Singleton	 Density	 Score	 (SDS)	 were	 not	 significant	
(P=0.20),	but	the	trend	was	towards	a	recent	increase	of	the	non-risk,	derived	allele	
T2.	By	contrast,	the	KLF14	transcript	does	exhibit	evidence	of	intolerance	to	variation	
in	the	ExAC	exome	aggregation	dataset3	(ExAC	constraint	scores:	Missense	z=	2.32;	
Synonymous	 z	 =	 2.41)	 suggesting	 coding	 changes	 in	 KLF14	 are	 under	 purifying	
selection.			
	
	
TwinsUK	Data	Extended	Methods	
 
Biopsy	 collection	Biopsies	and	blood	samples	 from	856	healthy	 female	 twins	 from	
the	 TwinsUK	 cohort	 were	 collected	 within	 the	 MuTHER	 project4.	 In	 short,	
subcutaneous	 adipose	 tissue	 punch	 biopsies	 from	 a	 photo-protected	 area	 of	 the	
stomach	 adjacent	 and	 inferior	 to	 the	 umbilicus	 were	 obtained	 from	 consented	
individuals	 and	 dissected	 to	 yield	 adipose	 and	 skin	 biopsies.	 Peripheral	 blood	
samples	were	also	collected	as	part	of	the	study	and	Lymphoblastoid	Cell	Lines	(LCLs)	
generated	 via	 transformation	 of	 the	B-lymphocyte	 fraction	with	 Epstein-Barr	 Virus	
(EBV).	
	
Genotypes	 The	 TwinsUK	 samples	 were	 genotyped	 on	 a	 combination	 of	 platforms	
(HumanHap300,	 HumanHap610Q,	 1M-Duo	 and	 1.2MDuo	 Illumina	 arrays)	 and	
samples	 were	 imputed	 using	 the	 1000	 Genomes5	 phase	 1	 reference	 panel	 using	
IMPUTE26	as	described	previously7.		
	
RNA-sequencing	 and	 quantification	 Adipose,	 skin,	 LCL	 and	 whole	 blood	 TwinsUK	
RNA	 samples	 were	 sequenced	 and	 quantified	 as	 previously	 described7.	 In	 short,	
reads	 were	 mapped	 to	 Gencode	 version	 10	 and	 variation	 in	 sequencing	 depth	
between	samples	was	corrected	by	normalizing	the	number	of	reads	to	the	median	
number	 of	well-mapped	 reads.	We	 used	 only	 exons	 that	were	 quantified	 in	more	
than	90%	of	 the	 individuals.	Exons	were	 rank-normal	 transformed	 for	downstream	
analysis.		
	
	
Preparation,	quality	control	and	genetic	analysis	of	large	cohorts	used	in	Sex	x	SNP	
interaction	analysis.	
	
UK	Biobank:	The	UK	Biobank	recruited	more	than	500,000	people	aged	37-73	years	
(99.5%	 were	 between	 40	 and	 69	 years)	 from	 across	 the	 country	 in	 2006-10.	
Participants	provided	a	range	of	information	via	questionnaires	and	interviews	(such	
as	demographics,	health	status,	and	lifestyle);	anthropometric	measurements,	blood	
pressure	 readings,	 and	 blood,	 urine	 and	 saliva	 samples	 were	 taken	 for	 future	
analysis.	This	has	been	described	in	more	detail	elsewhere8.	Genotype	data	from	the	
May	 2015	 release	 was	 available	 for	 a	 subset	 of	 152,249	 participants	 from	 UK	
Biobank.	 In	 addition	 to	 the	 quality	 control	 metrics	 performed	 centrally	 by	 UK	
Biobank,	we	defined	a	subset	of	“white	European”	ancestry	samples	(n=120,286)	as	
those	who	 both	 self-identified	 as	 white	 British	 and	were	 confirmed	 as	 ancestrally	
“Caucasian”	 using	 principal	 components	 analyses	 of	 genome-wide	 genetic	
information.	A	maximum	of	118,193	individuals	(62,165	females	and	56,027	males)	
with	genotype	and	valid	BMI,	height,	waist,	hip,	and	type	2	diabetes	measures	were	
available	 for	 downstream	 analyses.	 Prevalent	 type	 2	 diabetes	 status	 was	 defined	
using	self-reported	medical	history	and	medication	in	UK	Biobank	participants9.	The	
genotypes	 of	 the	 genetic	 variant	 were	 extracted	 from	 UK	 Biobank’s	 imputation	
dataset.	We	excluded	individual	genotypes	if	the	genotype	probability	was	less	than	
0.9.	We	converted	the	BMI,	height,	waist,	and	hip	measures	to	a	normal	distribution	
by	inverse	normalising	the	variables.	Each	analysis	was	adjusted	for	covariates:	age,	
age2,	sex,	six	(within	UK)	ancestry	principal	components,	and	array	used	to	measure	
genotypes.	
GERA:	The	Resource	for	Genetic	Epidemiology	on	Adult	Health	and	Aging	(GERA)	is	a	
large	multi-ethnic	population-based	cohort,	created	for	investigating	the	genetic	and	
environmental	 basis	 of	 age-related	 diseases	 [dbGaP	 phs000674.p1].	 T2D	 status	 is	
based	on	ICD-9	codes	in	linked	electronic	medical	health	records,	and	quality	control	
of	these	data	have	been	previously	described10.	We	extracted	6,961	T2D	cases	and	
13,922	controls	that	were	genotyped	using	a	custom	array	to	maximise	coverage	of	
common	 and	 low-frequency	 variation	 in	 non-Hispanic	 whites11.	 We	 used	 multi-
dimensional	 scaling	 in	 PLINK12	 to	obtain	 three	principal	 components	 to	 correct	 for	
population	 structure.	 The	autosomal	 genotype	 scaffold	was	 then	pre-phased	using	
SHAPEITv2.513.	 The	 resulting	 haplotypes	 were	 imputed,	 using	 an	 updated	
implementation	of	IMPUTE6,	up	to	the	Haplotype	Reference	Consortium	panel14.	The	
interaction	of	sex	with	rs4731702	was	evaluated	in	a	logistic	regression	model,	with	
adjustment	for	the	three	principal	components	as	covariates.	
	
WTCCC/	 UKT2D	 (The	 Wellcome	 Trust	 Case	 Control	 Consortium/United	 Kingdom	
Type	2	Diabetes	Genetics	consortium).	Details	of	the	samples	and	quality	control	of	
GWAS	data	have	been	previously	described15,15.	The	clean	genotype	data	was	pre-
phased	 using	 SHAPEITv2.513.	 The	 resulting	 haplotypes	 were	 imputed,	 using	 an	
updated	 implementation	 of	 IMPUTE6,	 up	 to	 the	 Haplotype	 Reference	 Consortium	
panel14.	The	genotypes	of	the	genetic	variant	were	extracted	from	imputed	dataset.	
We	excluded	individual	genotypes	if	the	genotype	probability	was	less	than	0.9.	The	
interaction	of	sex	with	rs4731702	was	evaluated	in	a	logistic	regression	model,	with	
adjustment	for	sex	as	covariate.	
	
Construction	of	Mouse	Models	
	
Klf14tm1(KOMP)Vlcg	 Deletion	 Mice	 The	 mouse	 strain	 (Klf14tm1(KOMP)Vlcg)	 used	 in	 this	
project	was	 generated	 from	 targeted	embryonic	 stem	 (ES)	 cells	 for	Klf14	 obtained	
from	 the	 KOMP	 repository	 www.komp.org,	 a	 NCRR-NIH	 supported	 mouse	
repository.		The	U42-RR024244	ES	cells	from	which	this	mouse	was	generated	were	
created	 by	 Velocigene	 from	 funds	 provided	 by	 the	 trans-HIH	 Knock-out	 Mouse	
Project	 (KOMP)	 (Grant	 number	 5U0101HG004085).	 Live	mice	were	 imported	 on	 a	
C57BL/6NTac	 USA	 background	 and	 rederived	 into	 the	 MRC	 Harwell	 Mary	 Lyon	
Centre	 specified	 pathogen	 free	 (SPF)	 facility	 and	 maintained	 on	 C57BL/6NTac.	
Klf14tm1(KOMP)Vlcg	 mice	 were	 kept	 and	 studied	 in	 accordance	 with	 UK	 Home	 Office	
legislation	 and	 local	 ethical	 guidelines	 issued	 by	 the	 Medical	 Research	 Council	
(Responsibility	 in	 the	Use	of	Animals	 for	Medical	Research,	 July	1993;	home	office	
license	30/3146).	
	
CRISPR-Cas9	 whole-body	 knockout	 The	 CRISPR-Cas9	whole-body	 knockout	mouse	
was	 generated	 using	 a	 guide	 RNA	 (gRNA)	 designed	 to	 target	 the	 beginning	 of	 the	
Klf14	 gene	 (Supplementary	 Table	 10).	 In	 vitro	 transcribed	Cas9	mRNA	 (100	 ng/μl;	
TriLink	 BioTechnologies)	 and	 gRNA	 (50	 ng/μl)	 were	 injected	 into	 cytoplasm	 of	
fertilized	 oocytes	 from	 C57BL/6J	 mice.	 Genomic	 DNA	 samples	 from	 founder	 mice	
were	screened	for	frameshift	mutations	by	PCR	and	confirmed	by	Sanger	sequencing	
(primers	 in	Supplementary	 Table	 11).	 The	most	 commonly	detected	mutant	 allele	
was	a	7-bp	deletion,	5’-GAGTGCC-3’,	and	founder	mice	with	this	allele	were	selected	
for	 breeding	 to	 obtain	 litters	with	 both	 homozygous	 knockout	mice	 and	wild-type	
mice	for	experiments.	
	
CRISPR-Cas9	 conditional	 knockout	 The	 CRISPR-Cas9	 conditional	 knockout	 mouse	
was	generated	using	two	gRNAs	designed	to	target	sites	upstream	and	downstream	
of	 the	Klf14	 gene;	 two	 single-strand	DNA	oligonucleotides	 bearing	 loxP	 sequences	
along	with	 80-nt	 homology	 arms	matching	 the	 target	 sites	were	 synthesized	 (IDT)	
(Supplementary	 Table	 10).	 In	 vitro	 transcribed	Cas9	mRNA	 (100	ng/μl)	 and	gRNAs	
(25	 ng/μl	 each)	 and	 single-strand	 DNA	 oligonucleotides	 (100	 ng/μl	 each)	 were	
injected	 into	 cytoplasm	 of	 fertilized	 oocytes	 from	 C57BL/6J	 mice.	 Genomic	 DNA	
samples	from	founders	were	screened	for	correct	loxP	sequences	flanking	the	Klf14	
gene	by	PCR	and	confirmed	by	Sanger	sequencing	(primers	in	Supplementary	Table	
11).	Offspring	of	founder	mice	with	correct	loxP	sequences	were	screened	to	identify	
those	in	which	the	two	loxP	sequences	segregated	on	the	same	chromosome.	Those	
mice	 were	 bred	 for	 multiple	 generations	 with	 Adipoq-Cre	 mice	 of	 the	 C57BL/6J	
background	[B6;FVB-Tg(Adipoq-cre)1Evdr/J,	The	Jackson	Laboratory]	to	obtain	litters	
with	both	homozygous	Klf14	 loxP	knock-in	mice	and	wild-type	mice	that	were	also	
positive	for	Adipoq-Cre	for	experiments.	The	presence	of	the	Adipoq-Cre	allele	was	
confirmed	by	PCR	(primers	in	Supplementary	Table	11).	
	
Gene	Expression	in	Mouse	Models	
	
Klf14tm1(KOMP)Vlcg	 Deletion	Mice	RNA	was	extracted	 from	snap	 frozen	subcutaneous	
tissue,	isolated	at	the	same	time	of	day,	using	phenol	chloroform	and	a	RNeasy	Mini	
Kit	 (Qiagen,	 UK)	 according	 to	 the	 manufacture’s	 instructions.	 RNA	 integrity	 was	
assessed	 using	 a	 2100	Bioanalyzer	 (Agilent	 Technologies)	 and	 samples	with	 a	 RNA	
integrity	 (RIN)	 number	 of	 8	 and	 above	 (N=4/group)	 were	 selected	 for	 RNASeq	
analysis.	 These	 samples	were	 sent	 to	 the	Oxford	Genomics	 centre	where	a	quality	
control	 report	 was	 generated	 and	 a	 library	 of	 read	 data	 compiled.	 Differentially	
expressed	 genes	 were	 identified	 by	 comparing	 the	 RNAseq	 profiles	 of	 male	 mice	
inheriting	the	Klf14tm1(KOMP)Vlcg	deletion	allele	from	their	mother	(resulting	in	no	Klf14	
expression)	to	male	mice	inheriting	the	deletion	allele	from	their	father	(maintained	
expression	from	the	maternally	inherited	non-deletion	allele).		
	
	
CRISPR-Cas9	 conditional	 knockout	 RNA	 was	 extracted	 from	 snap-frozen	
subcutaneous	adipose	 tissue	 from	4-month-old	 littermates	 (n	=	2	 females,	2	males	
each	 of	 wild-type	 and	 adipose-specific	 knockout	 mice)	 using	 TRIzol	 RNA	 Isolation	
Reagent	 according	 to	 the	 manufacturer’s	 instructions	 (Thermo	 Fisher	 Scientific).	
Library	generation	and	RNA	sequencing	were	performed	at	the	Bauer	Core	Facility	of	
Harvard	 University.	 On	 average,	 about	 25	 million	 75-bp	 single-end	 reads	 were	
obtained	 for	 each	 sample	 on	 the	 Illumina	 NextSeq	 500	 platform.	 	 Differentially	
expressed	genes	were	identified	by	comparing	the	RNAseq	profiles	of	knockout	mice	
to	wile-type	mice.		
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Cohort Samples Platform Female:Male Population Citation 
TwinsUK 776 RNAseq 100:0 Healthy female twins from 
the United Kingdom 
Buil et al, Nature 
Genetics 2015 
METSIM 770 Affymetrix 
U219 array 
0:100 Healthy men from Finland Civelek et al, AJHG 2017 
deCODE 589 Agilent array 58:42 Healthy men and women 
from Iceland 
Emilsson et al, Nature, 
2008	
MGH 701 Agilent array 75:25 Obese bariatric surgery 
patients from USA 
Greenawalt et al, 
Genome Research 2011 
	
Supplementary	Table	2|	Characteristics	of	subcutaneous	adipose	gene	expression	
cohorts	used	in	trans-network	replication	
	
	
	 	
Tissue Source Platform N Cis-eQTL P  Trans-Eqtl present 
Subcutaneous Adipose TwinsUK RNAseq 776 1.8 x10-36 Yes 
Subcutaneous Adipose METSIM Microarray 770 2.4 x10-6 Yes 
Subcutaneous Adipose deCODE Microarray 589 2.6 x10-10 Yes 
Subcutaneous Adipose deCODE maternal Microarray 589 6.6 x10-20 Yes 
Subcutaneous Adipose MGH, Greenawalt et al Microarray 701 1.6 x10-11 Yes 
Omental Adipose MGH, Greenawalt et al Microarray 848 3.6 x10-7 Yes 
Subcutaneous Adipose GTEx RNAseq 298 0.0001 Yes 
Visceral Adipose GTEx RNAseq 185 0.97 Yes 
Skin TwinsUK RNAseq 672 0.79 No 
Lymphoblastoid Cell Line TwinsUK RNAseq 765 Not expressed No 
Whole Blood TwinsUK RNAseq 368 Not expressed No 
Skeletal Muscle Keildson et al Microarray 200 Not significant No 
Skeletal Muscle GTEx RNAseq 361 Not significant No 
Pancreatic Islets Van de Bunt et al RNAseq 118 Not significant No 
Monocytes Zeller et al Microarray 1,490 Not significant NA 
Liver MGH, Greenawalt et al Microarray 651 Not significant No 
Liver Innocenti et al Microarray 266 Not significant NA 
Whole Blood Westra et al RNAseq & Microarray 5,311 Not significant No 
Monocytes/Macrophages Cardiogenics Microarray 758 Not significant NA 
Dendritic Cells PhenoGenetic Microarray 534 Not significant NA 
CD4+ T Cells Raj et al Microarray 407 Not significant NA 
CD19+ B cells Fairfax et al Microarray 283 Not significant NA 
Lung Hao et al Microarray 1,111 Not significant NA 
10 Brain regions 
UK Brain Expression 
Consortium, Ramasamy 
et al 
Microarray 134 Not significant No 
Remaining 41 GTEx tissues GTEx RNAseq 70-338 Not significant No 
	
Supplementary	 Table	 3	 |	KLF14	 cis-eQTL	 is	 limited	 to	 adipose	 tissue.	Association	
between	 KLF14	 expression	 and	 T2D	 associated	 SNP	 rs4731702.	 Most	 published	
studies	only	report	summary	statistics	for	significant	eQTLs	–	‘Not	significant’	means	
the	study	did	not	find	a	cis-eQTL	between	rs4731702	KLF14,	in	some	cases	this	may	
mean	 KLF14	 was	 not	 expressed	 in	 that	 tissue.	 	 The	 trans-eQTL	 was	 considered	
present	if	at	least	one	trans-gene	had	P	<	0.05,	Bonferonni	corrected	for	the	number	
of	 trans-genes	 quantified	 in	 that	 dataset.	 	 Datasets	 where	 trans-analysis	 or	 raw	
genotypes	were	unavailable	are	marked	‘NA’.				
	 	
	
Test Sample P   Standard Error 
Standard All 2.6 x 10-10 -0.023 0.0036 
Maternal Allele All 6.6 x 10-20 -0.046 0.0049 
Paternal Allele All 0.89 -0.001 0.0051 
Standard Females 1.1 x 10-05 -0.020 0.0045 
Standard Males 1.5 x 10-06 -0.027 0.0056 
Maternal Allele Females 4.1 x 10-11 -0.044 0.0064 
Maternal Allele Males 5.5 x 10-11 -0.051 0.0074 
Paternal Allele Females 0.96 -0.0003 0.0066 
Paternal Allele Males 0.85 0.002 0.0077 
	
Supplementary	Table	4	|	Sex-stratified	and	parent	of	origin	effects	on	 the	KLF14	
cis-eQTL.	 Association	 between	 rs4731702	 and	 adipose	 expression	 of	 KLF14	 in	 the	
deCODE	 dataset	 (female	 N=376	 and	 male	 N=265).	 The	 T2D	 risk	 allele	 C	 is	 the	
reference	allele.		
	
	
	 	
	
	
 
 KLF14 expression 
x Trait Genes associated to trait (%) 
Enrichment for 
association in KLF14 
network 
Trait 
 
P Direction KLF14 Network genes 
All expressed 
genes excluding 
KLF14 Network 
OR 
 
P 
Combined Insulin 
Resistance 
Phenotype* 
 
1.08 x 10-3 - 151 (39%) 5,261 (28%) 1.66 
 
1.82 x 10-6 
Fasting Insulin  8.08 x 10-6 - 200 (52%) 7,254 (39%) 1.70  1.88 x 10-7 
Fasting Glucose  1.63 x 10-6 - 10 (3%) 301 (2%) 1.63  0.10 
HOMA-IR  5.73 x 10-7 - 200 (52%) 7,234 (39%) 1.73  8.82 x 10-8 
BMI  0.90 - 373 (97%) 16,472 (88%) 4.38  9.08 x 10-10 
HDL  0.04 + 300 (78%) 12,014 (65%) 1.96  8.28 x 10-9 
LDL  0.76 - 3 (0.78%) 68 (0.36%) 2.16  0.17 
Triglycerides  0.51 - 267 (70%) 10,585 (57%) 1.76  1.78 x 10-7 
Whole Body Fat  0.12 - 139 (36%) 4,680 (25%) 1.68  1.47 x 10-6 
Waist-hip ratio  0.09 - 140 (36%) 4,511 (24%) 1.81  5.97 x 10-8 
Android/Gynoid 
Ratio  1.75 x 10
-3 - 314 (82%) 12,706 (68%) 2.12  9.55 x 10-10 
Adiponectin  0.90 - 46 (12%) 1,295 (7%) 1.81  3.313 x 10-4 
Leptin  0.65 - 13 (4%) 249 (2%) 2.60  2.60 x 10-3 
	
Supplementary	Table	7	|	Expression	of	KLF14	and	the	385	trans-genes	are	enriched	
for	 association	 to	 concurrently	 measured	 metabolic	 traits.	 Association	 between	
adipose	 expression	 in	 TwinsUK	 (N	 =	 776	 females)	 and	 concurrently	 measured	
metabolic	traits.	All	associations	were	adjusted	for	body-mass	index	(BMI),	except	to	
BMI	 itself.	 	 In	 KLF14	 expression	 vs	 Trait	 columns,	 P	 reports	 the	 p	 value	 of	 the	
association	 between	 KLF14	 expression	 and	 the	 corresponding	 trait	 and	 Direction	
reports	 whether	 the	 association	was	 direct	 (+)	 or	 inverse	 (-).	 Genes	 associated	 to	
trait	columns	list	the	number	of	genes	in	each	category	which	were	associated	to	the	
respective	 trait	 at	 FDR	 5%.	 Significance	 of	 enrichment	 for	 trait-association	 in	 the	
KLF14	network	genes	compared	to	all	adipose	genes	was	assessed	using	a	one-tailed	
Fisher’s	 exact	 test.	 OR,	 odds	 ratio;	 BMI,	 body-mass	 index,	 HDL,	 high	 density	
lipoprotein;	 LDL,	 low	 density	 lipoprotein.	 *Association	 with	 insulin	 resistance	 was	
assessed	via	a	combined	insulin	resistance	phenotype	consisting	of	association	with	
fasting	 insulin,	 HDL	 and	 triglycerides	 with	 a	 directionality	 consistent	 with	 risk	 or	
protection	from	a	phenotype	of	insulin	resistance. 
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PCR	primer	 Oligonucleotide	sequence	
Klf14	whole-body	knockout	forward	 5’-AGCTCGTCTGGCTCCAAG-3’	
Klf14	whole-body	knockout	reverse	 5’-GGGCACCACAGCTTAAATCA-3’	
Klf14	conditional	knockout	upstream	forward	 5’-TTCTATTTCAAGCGGGGATG-3’	
Klf14	conditional	knockout	upstream	reverse	 5’-CTTGTCTGCGCTTTCTCTCC-3’	
Klf14	conditional	knockout	downstream	forward	 5’-GCAGGCTGTTTGGAAGAAAC-3’	
Klf14	conditional	knockout	downstream	reverse	 5’-CATGGTGGAAAGCTCTGGTT-3’	
Adipoq-Cre	forward	 5’-GGATGTGCCATGTGAGTCTG-3’	
Adipoq-Cre	reverse	 5’-ACGGACAGAAGCATTTTCCA-3’	
	
Supplementary	Table	11	|	PCR	primers	used	in	CRISPR-Cas9	mouse	models	
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